[Articles] Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial

Journal content Created on 25 Aug 2026 The Lancet Oncology

• Details
• • All feed content
  • My feed content